MARC Record from harvard_bibliographic_metadata

LEADER: 02735cam a22004578i 4500
001 013500715-1
005 20130206101337.0
008 121019s2013 nyua b 001 0 eng
010 $a 2012038902
020 $a9780865478008 (alk. paper)
020 $a0865478007 (alk. paper)
035 0 $aocn814389713
040 $aDLC$beng$erda$cDLC$dOCLCO
042 $apcc
050 00 $aRM301.27$b.G65 2013
060 4 $aQV 736
082 00 $a615.1072/4$223
100 1 $aGoldacre, Ben.
245 10 $aBad pharma :$bhow drug companies mislead doctors and harm patients /$cBen Goldacre.
250 $aFirst American edition.
264 1 $aNew York :$bFaber and Faber, Inc., an affiliate of Farrar, Straus and Giroux,$c2013.
300 $axvii, 426 p. :$bill. ;$c22 cm.
336 $atext$2rdacontent
337 $aunmediated$2rdamedia
338 $avolume$2rdacarrier
504 $aIncludes bibliographical references and index.
505 0 $aIntro -- Missing data -- Where do new drugs come from? -- Bad regulators -- Bad trials -- Bigger, simpler trials -- Marketing -- Afterword: better data.
520 $aWe like to imagine that medicine is based on evidence and the results of fair tests. In reality, those tests are often profoundly flawed. We like to imagine that doctors are familiar with the research literature about a drug, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality much of their education is funded by the pharmaceutical industry. We like to imagine that regulators let only effective drugs onto the market, when in reality they approve useless drugs, with data on side effects casually withheld from doctors and patients. All these problems have been shielded from public scrutiny because they're too complex to capture in a sound bite. But Ben Goldacre shows that the true scale of this murderous disaster fully reveals itself only when the details are untangled. He believes we should all be able to understand precisely how data manipulation works and how research misconduct on a global scale affects us. This book reveals a shockingly broken system and calls for something to be done.--From publisher description.
650 0 $aDrugs$xTesting.
650 0 $aDrugs$xTesting$xMoral and ethical aspects.
650 0 $aClinical trials$xMoral and ethical aspects.
650 0 $aPharmaceutical industry$xMoral and ethical aspects.
650 0 $aDrugs$xQuality control.
650 12 $aDrug Industry$xethics.
650 22 $aClinical Trials as Topic$xethics.
650 22 $aDrug Approval$xethics.
899 $a415_565580
899 $a430_586760
988 $a20121130
049 $aKSGG
906 $0DLC